Tracing the path of 37,050 studies into practice across 18 specialties of the 2.4 million published between 2011-2020

  1. Moustafa Abdalla  Is a corresponding author
  2. Salwa Abdalla
  3. Mohamed Abdalla
  1. Harvard Medical School, United States
  2. University of Toronto, Canada

Abstract

The absence of evidence to assess treatment efficacy partially underpins the unsustainable expenditure of the US healthcare system; a challenge exacerbated by a limited understanding of the factors influencing the translation of clinical research into practice. Leveraging a dataset of >10,000 UpToDate articles, sampled every 3 months between 2011-2020, we trace the path of research (37,050 newly added articles from 887 journals) from initial publication to the point-of-care, compared to the 2.4 million uncited studies published during the same time window across 18 medical specialties. Our analysis reveals substantial variation in how specialties prioritize/adopt research, with regards to fraction of literature cited (0.4%-2.4%) and quality-of-evidence incorporated. In 9 of 18 specialties, less than 1 in 10 clinical trials are ever cited. Further, case reports represent one of the most cited article types in 12 of 18 specialties, comprising nearly a third of newly-added references for some specialties (e.g., dermatology). Anesthesiology, cardiology, critical care, geriatrics, internal medicine, and oncology tended to favor higher-quality evidence. By modelling citations as a function of NIH department-specific funding, we estimate the cost of bringing one new clinical citation to the point-of-care as ranging from thousands to tens of thousands of dollars depending on specialty. The success of a subset of specialties in incorporating a larger proportion of published research, as well as high(er) quality of evidence, demonstrates the existence of translational strategies that should be applied more broadly. In addition to providing a baseline for monitoring the efficiency of research investments, we also describe new 'impact' indices to assess the efficacy of reforms to the clinical scientific enterprise.

Data availability

We used the citation lists of all UpToDate articles published between 2011-2020. While all these citation lists are/were publicly available, we recognize the amount of work and effort required to collate and pre-process this data. As such, we have made publicly available the entire dataset used in this analysis to all readers at: https://www.8mlabs.org/uptodate/rawdataset

Article and author information

Author details

  1. Moustafa Abdalla

    Department of Surgery, Harvard Medical School, Boston, United States
    For correspondence
    moustafa_abdalla@hms.harvard.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2481-9753
  2. Salwa Abdalla

    Department of Computer Science, University of Toronto, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  3. Mohamed Abdalla

    Department of Computer Science, University of Toronto, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.

Funding

The authors declare that there was no funding for this work.

Copyright

© 2023, Abdalla et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 529
    views
  • 78
    downloads
  • 1
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Moustafa Abdalla
  2. Salwa Abdalla
  3. Mohamed Abdalla
(2023)
Tracing the path of 37,050 studies into practice across 18 specialties of the 2.4 million published between 2011-2020
eLife 12:e82498.
https://doi.org/10.7554/eLife.82498

Share this article

https://doi.org/10.7554/eLife.82498

Further reading

    1. Medicine
    Hyun Beom Song, Laura Campello ... Anand Swaroop
    Research Advance

    Inherited retinal degenerations (IRDs) constitute a group of clinically and genetically diverse vision-impairing disorders. Retinitis pigmentosa (RP), the most common form of IRD, is characterized by gradual dysfunction and degeneration of rod photoreceptors, followed by the loss of cone photoreceptors. Recently, we identified reserpine as a lead molecule for maintaining rod survival in mouse and human retinal organoids as well as in the rd16 mouse, which phenocopy Leber congenital amaurosis caused by mutations in the cilia-centrosomal gene CEP290 (Chen et al., 2023). Here, we show the therapeutic potential of reserpine in a rhodopsin P23H rat model of autosomal dominant RP. At postnatal day (P) 68, when males and females are analyzed together, the reserpine-treated rats exhibit higher rod-derived scotopic b-wave amplitudes compared to the controls with little or no change in scotopic a-wave or cone-derived photopic b-wave. Interestingly, the reserpine-treated female rats display enhanced scotopic a- and b-waves and photopic b-wave responses at P68, along with a better contrast threshold and increased outer nuclear layer thickness. The female rats demonstrate better preservation of both rod and cone photoreceptors following reserpine treatment. Retinal transcriptome analysis reveals sex-specific responses to reserpine, with significant upregulation of phototransduction genes and proteostasis-related pathways, and notably, genes associated with stress response. This study builds upon our previously reported results reaffirming the potential of reserpine for gene-agnostic treatment of IRDs and emphasizes the importance of biological sex in retinal disease research and therapy development.

    1. Medicine
    Zhen Wang, Jie Zhu ... Xiang Zhou
    Research Article

    The incidence of post-cardiac arrest myocardial dysfunction (PAMD) is high, and there is currently no effective treatment available. This study aims to investigate the protective effects of exogenous mitochondrial transplantation in Sprague-Dawley (SD) rats. Exogenous mitochondrial transplantation can enhance myocardial function and improve the survival rate. Mechanistic studies suggest that mitochondrial transplantation can limit impairment in mitochondrial morphology, augment the activity of mitochondrial complexes II and IV, and raise ATP level. As well, mitochondrial therapy ameliorated oxidative stress imbalance, reduced myocardial injury, and thus improved PAMD after cardiopulmonary resuscitation (CPR).